Biocon Limited has informed the Exchange regarding 'Company Statement'.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The U.S. FDA conducted a Pre-License Inspection (PLI) at Biocon's biosimilars manufacturing site in Bengaluru from April 20-29, 2026. The inspection covered 3 Biologics Manufacturing units, 5 Quality testing laboratories, and 2 warehouses. FDA issued a Form 483 with 5 observations, all of which are procedural in nature and do not relate to data integrity or quality oversight issues. No repeat observations were noted. Biocon plans to submit a comprehensive Corrective and Preventive Action (CAPA) plan within the required timeframe and is confident of addressing all observations.
This is a positive regulatory development as the FDA inspection has been completed without any major data integrity concerns. The procedural observations can be addressed through the CAPA plan, keeping Biocon on track for biosimilar product approvals for the U.S. market.